SCG Cell Therapy’s SCG142 Receives FDA IND Clearance for HPV-Associated Solid Tumors

SINGAPORE, July 1, 2024 — SCG Cell Therapy Pte Ltd (SCG), a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, today announced that U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate Phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus (HPV) …